(Q58691159)

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

Epidemiology and etiology of gliomas

1 reference

https://api.crossref.org/works/10.5402%2F2012%2F530179

The 2007 WHO classification of tumours of the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.5402%2F2012%2F530179

Histology and molecular pathology of pediatric brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.5402%2F2012%2F530179

Combined surgery, radiation, and PCV chemotherapy for astrocytomas compared to oligodendrogliomas and oligoastrocytomas WHO grade III.

21 January 2018

1 reference

https://api.crossref.org/works/10.5402%2F2012%2F530179

High-grade astrocytoma in very young children.

21 January 2018

1 reference

https://api.crossref.org/works/10.5402%2F2012%2F530179

Multi-institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.5402%2F2012%2F530179

Temozolomide in the treatment of recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.5402%2F2012%2F530179

Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.5402%2F2012%2F530179

Temozolomide chemotherapy in recurrent oligodendroglioma

21 January 2018

1 reference

https://api.crossref.org/works/10.5402%2F2012%2F530179

Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972.

21 January 2018

1 reference

https://api.crossref.org/works/10.5402%2F2012%2F530179

Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971.

21 January 2018

1 reference

https://api.crossref.org/works/10.5402%2F2012%2F530179

Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group

21 January 2018

1 reference

https://api.crossref.org/works/10.5402%2F2012%2F530179

Technical advancement in regulatory T cell isolation and characterization using CD127 expression in patients with malignant glioma treated with autologous dendritic cell vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.5402%2F2012%2F530179

In vivo bioluminescence imaging in an experimental mouse model for dendritic cell based immunotherapy against malignant glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.5402%2F2012%2F530179

DC vaccination with anti-CD25 treatment leads to long-term immunity against experimental glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.5402%2F2012%2F530179

Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.5402%2F2012%2F530179

Adjuvant dendritic cell-based tumour vaccination for children with malignant brain tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.5402%2F2012%2F530179

Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.5402%2F2012%2F530179

Dendritic cell vaccination in patients with malignant gliomas: current status and future directions.

21 January 2018

1 reference

https://api.crossref.org/works/10.5402%2F2012%2F530179

Tumor vaccination for malignant brain tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.5402%2F2012%2F530179

Dendritic cell therapy of high-grade gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.5402%2F2012%2F530179

Prostate cancer as a model for tumour immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.5402%2F2012%2F530179

Vaccine therapy in patients with renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.5402%2F2012%2F530179

Immunotherapy for melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.5402%2F2012%2F530179

Dendritic cell vaccines for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.5402%2F2012%2F530179

A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding

21 January 2018

1 reference

https://api.crossref.org/works/10.5402%2F2012%2F530179

Uptake and presentation of malignant glioma tumor cell lysates by monocyte-derived dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.5402%2F2012%2F530179

Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study

21 January 2018

1 reference

https://api.crossref.org/works/10.5402%2F2012%2F530179

Prognostic factors in pediatric high-grade astrocytoma: the importance of accurate pathologic diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.5402%2F2012%2F530179

Genetic alterations and signaling pathways in the evolution of gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.5402%2F2012%2F530179

IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.5402%2F2012%2F530179

Genetic pathways to glioblastoma: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.5402%2F2012%2F530179

IDH1 and IDH2 mutations in gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.5402%2F2012%2F530179

Methylation of O6-methylguanine DNA methyltransferase and loss of heterozygosity on 19q and/or 17p are overlapping features of secondary glioblastomas with prolonged survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.5402%2F2012%2F530179

Long-term outcome of oligodendrogliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.5402%2F2012%2F530179

Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.5402%2F2012%2F530179

Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.5402%2F2012%2F530179

Efficacy and feasibility of standard procarbazine, lomustine, and vincristine chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy. A Phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.5402%2F2012%2F530179